Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Environ Toxicol Chem ; 37(10): 2566-2574, 2018 10.
Article in English | MEDLINE | ID: mdl-29923627

ABSTRACT

Australian freshwaters have relatively low water hardness and different calcium (Ca) to magnesium (Mg) ratios compared with those in Europe. The hardness values of a substantial proportion of Australian freshwaters fall below the application boundary of the existing European nickel biotic ligand models (Ni BLMs) of 2 mg Ca/L. Toxicity testing was undertaken using Hydra viridissima to assess the predictive ability of the existing Ni BLM for this species in extremely soft waters. This testing revealed an increased competitive effect of Ca and Mg with Ni for binding to the biotic ligand in soft water (<10 mg CaCO3 /L) than at higher water hardness. Modifications were made to the Ni BLM by increasing the binding constants for Ca and Mg at the biotic ligand to account for softer waters encountered in Australia and the more important competitive effect of Ca and Mg on Ni toxicity. To validate the modified Ni BLM, ecotoxicity testing was performed on 5 Australian test species in 5 different natural Australian waters. Overall, no single water chemistry parameter was able to indicate the trends in toxicity to all of the test species. The modified Ni BLMs were able to predict the toxicity of Ni to the test species in the validation studies in natural waters better than the existing Ni BLMs. The present study suggests that the overarching mechanisms defining Ni bioavailability to freshwater species are globally similar and that Ni BLMs can be used in all freshwater systems with minor modifications. Environ Toxicol Chem 2018;37:2566-2574. © 2018 SETAC.


Subject(s)
Aquatic Organisms/drug effects , Fresh Water , Models, Theoretical , Nickel/toxicity , Animals , Australia , Biological Availability , Calcium/analysis , Hydra/drug effects , Ligands , Magnesium/analysis , Reproducibility of Results , Species Specificity , Toxicity Tests , Water Pollutants, Chemical
2.
Cell Rep ; 4(6): 1116-30, 2013 Sep 26.
Article in English | MEDLINE | ID: mdl-24055055

ABSTRACT

To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes. Structural and copy number aberrations were found to be retained with high fidelity. However, at the single-nucleotide level, variable numbers of PDX-specific somatic events were documented, although they were only rarely functionally significant. Variant allele frequencies were often preserved in the PDXs, demonstrating that clonal representation can be transplantable. Estrogen-receptor-positive PDXs were associated with ESR1 ligand-binding-domain mutations, gene amplification, or an ESR1/YAP1 translocation. These events produced different endocrine-therapy-response phenotypes in human, cell line, and PDX endocrine-response studies. Hence, deeply sequenced PDX models are an important resource for the search for genome-forward treatment options and capture endocrine-drug-resistance etiologies that are not observed in standard cell lines. The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Estrogen Receptor alpha/genetics , Adaptor Proteins, Signal Transducing/genetics , Alleles , Animals , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Drug Resistance, Neoplasm , Estradiol/pharmacology , Female , Gene Amplification , Genomic Instability , Heterografts , Humans , Mice , Neoplasm Proteins/biosynthesis , Neoplasm Proteins/genetics , Neoplasm Staging , Phosphoproteins/genetics , Point Mutation , RNA, Neoplasm/biosynthesis , RNA, Neoplasm/genetics , Transcription Factors , Translocation, Genetic , YAP-Signaling Proteins
3.
J Bus Contin Emer Plan ; 5(1): 462-73, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21482514

ABSTRACT

London will host the Olympic and Paralympic Games in 2012. Hosting the Games brings with it both opportunities and challenges for the capital and country. The National Health Service (NHS) in London has a crucial role to play in the delivery of a safe and secure Games. It must also protect its business as usual services and be prepared to respond to any enhanced or additional threats and hazards that may be created by the presence of the Games. NHS London leads a programme of work to ensure that the NHS fulfils its responsibilities during the Games. The programme's Health Resilience workstream has adopted a structured planning process to assess risks, identify gaps in the capability of the NHS, and ensure those gaps are addressed prior to the Games. It acknowledges that training, exercising and testing play vital roles in capability. This work aims to ensure that London's health services will respond in a timely, proportionate and appropriate manner to any incident during the Games. This paper gives an overview of the Olympic context within which this resilience work is taking place, and details the planning processes and relationships employed in planning for such a major event.


Subject(s)
Anniversaries and Special Events , Community Health Planning/organization & administration , Emergency Medical Services/organization & administration , Sports , Community-Institutional Relations , Humans , London , Risk Management , State Medicine
SELECTION OF CITATIONS
SEARCH DETAIL
...